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Introduction
Recently, international harmonization 
guidelines have been promoted including 
examination of approval documents for new 
pharmaceuticals, to accelerate superior phar-
maceutical research and development and 
availability of drugs to patients.　For this 
purpose, the International Council on Har-
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要　旨
２０１４年に日本で承認された新医療用製剤に対し、安定性試験の現状を調査した。我々は、２０１４年に安
定性試験の記述がある１３４の新医療用製剤を特定した。長期保存試験としては、８２製剤が２５±２℃/６０±
５％相対湿度の条件下で、４８製剤が５±３℃の条件下で、４　 製剤が１０℃未満の条件下で試験が実施され
ていた。また、光安定性試験では、７８製剤が光学的に安定であったが、４８製剤は光学的に不安定であっ
た．光学的に不安定な製剤は、遮光保存をするといった適切な保存方法がとられている．これらの結果
から、２０１４年に日本で承認された新医療用製剤は、ICH ガイドラインに従って、適正に承認されている
ことがわかった。
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Abstract
We investigated the current status of stability testing of new drug products in Japan.　One 
hundred thirty-four new drug products that had undergone stability testing in ２０１４ were identified.　
Among these, ８２ were tested at ２５℃±２℃/６０％±５％ relative humidity, ４８ were tested at ５℃±３℃, 
and ４ were tested at less than １０℃ on long-term testing.　Based on photostability testing, ７８ new 
drug products were found to be optically stable and ４８ were optically unstable.　New drug products 
that appeared unstable in photostability testing were stored in the dark.　Based on these results, 
the new drug products approved in Japan according to the ICH guidelines in ２０１４ were found to 
have been adequately tested.
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stability testing, new drug product, long-term testing, accelerated testing, photostability testing, 
guideline
原　著　論　文 
monisation of Technical Requirements for 
Registration of Pharmaceuticals for Human 
Use（ICH）has been organized to promote 
harmonization.
Stability testing is an essential require-
ment for New Drug Applications.　Therefore, 
many guidelines for stability testing of new 
drug products are provided in ICH.１５）　The 
guidelines for stability testing of new drug 
products are listed in Table １.
ICHQ１A（R２）defines the stability data 
package for new drug substances or drug 
products that is sufficient for a registration 
application within the three regions of the 
European Union, Japan, and the United 
States.１）
ICHQ１B states that the intrinsic photo-
stability characteristics of new drug sub-
stances and products should be evaluated to 
demonstrate that light exposure does not 
cause unacceptable changes.２）
ICHQ１C is an annex to ICHQ１A（R２）
and provides recommendations on the data 
that should be submitted regarding the sta- 
bility of new dosage forms by the original 
applicant, after the original submission for 
new drug substances and products.３）
ICHQ１D provides recommendations on 
the application of bracketing and matrixing to 
stability studies.４）　Bracketing can be applied 
to studies with multiple strengths of identical 
or closely related formulations, and matrixing 
designs can be applied to strengths with 
identical or closely related formulations.
ICHQ１E provides recommendations on 
how to use stability data generated in accor-
dance with the principles detailed in ICHQ１A
（R２）, which can be used to propose a retest 
periods or shelf life in a registration appli- 
cation.５）　Further, this guideline describes 
when and how extrapolation can be considered 
when proposing a retest period for a drug 
substance or a shelf life for a drug product 
that extends beyond the period covered by
“available data from the stability studies 
under the long-term storage condition.”５）
In New Drug Application, long-term 
studies and acceleration studies must be 
included in stability testing according to ICH
Q１A（R２）.
We analyzed data on the stability testing 
of drug products that were approved by the 
Japanese government in ２０１４ and discuss our 
findings in this article.
MATERIALS AND METHODS
Drugs that were approved from January 
to December ２０１４ were surveyed.　The infor-
mation sources were the data summaries 
［Module ２ of Common Technical Document
（CTD）in the present system］that were 
submitted by the applicants in New Drug 
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Table １　Guidelines for stability testing of new drug products
AbbreviationName of the Guideline
ICHQ1A（R2）Stability Testing of New Drug Substances and Products
ICHQ1BStability Testing: Photostability Testing of New Drug Substances and Products,
ICHQ1CStability Testing for New Dosage Forms
ICHQ1DBracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
ICHQ1EEvaluation of Stability Data,
Application and approval documents, which 
described specifications and test methods of 
the drug substances.　This information, es- 
pecially that in the quality sections, is not all 
publicly available, although Module ２ of CTD 
and review reports are available on the Inter- 
net.６）　Therefore, we did not disclose the 
individual substance’ names.
RESULTS AND DISCUSSION
Classification of Approved Drugs by 
Stability Testing
One hundred thirty-four new drug prod-
ucts approved from January to December 
２０１４, excluding antiseptics for medical devices, 
in vivo diagnostics products, and generic drugs. 
Of these, four were additional dosage forms
（Fig. １）.
We investigated further details of the １３４ 
new drug substances as shown in the follow-
ing sections.
Long-Term Testing and Accelerated Testing
According to ICHQ１A（R２）,１） long-term 
testing for general new drug products is 
performed at ２５℃±２℃/６０％±５％ relative hu- 
midity（RH）or ３０℃±２℃/６５％±５％ RH.　
Accelerated testing for general new drug prod- 
ucts is performed at ４０℃±２℃/７５％±５％ RH. 
In the case of drug products intended to be 
stored in a refrigerator, long-term testing is 
performed at ５℃±３℃, and accelerated testing 
is performed at ２５℃±２℃/６０％±５％ RH.　In 
the case of drug products intended to be sto- 
red in a freezer, long-term testing is per-
formed at －２０℃±５℃.　 Further, long-term 
testing of drug products intended to be stored 
below －２０℃ is performed on a case-by-case 
basis.
Long-term testing was performed for ８２ 
new drug products at ２５℃±２℃/６０％±５％ RH, 
for ４８ products at ５℃±３℃, and for ４ at ＜１０℃ 
without freezing（Table ２）.
Among these new drug products, the 
storage period ＞ ３６ months for ３５ products, 
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Fig. １　Classification of new drug products according to whether or not they 
　　　 underwent stability testing
３０ months for two, ２４ months for ６４, ２１ 
months for four, １９ months for one, １８ 
months for １５, １５ months for one, １３ months 
for one, and １２ months for １１（Table ２）.　All 
periods satisfied the minimum duration recom-
mended ICHQ１A.１）
Expiration dates of ３９ new drug products 
to which ICHQ１E５） was applicable were post- 
poned（Fig. ２）.
Based on ICHQ１D,４） in seven cases, a 
bracketing method was applied for stability 
testing of new drug products.　According 
to ICHQ１A１） and ICHQ１D,４） a bracketing 
method is applied to different, container sizes 
or different fills in the same container closure 
system.　Because it is not necessary for an 
applicant to use this method for new drug 
products, very few applicants utilize method. 
The potential risk is that a shorter shelf life 
may be established than the one derived from 
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Table ２　Specifications of storage temperatures and conservative period used in
long-term　　　　　　　　　　　　　　　　　　　　　　　　　
Number of New Drug ProductsStorage PeriodStorage Condition
２６３６ months
２５℃±２℃/６０％±５％ RH
１３０ months
３５２４ months
１１９ months
１２１８ months
１１５ months
１１３ months
５１２ months
１３６ months
＜１０℃ without freezing １３０ months
２１２ months
８３６ months
５℃±３℃
２９２４ months
４２１ months
３１８ months
４１２ months
Fig. ２　Proportion of ICHQ１E applications
a full design due to the reduced amount of 
data collected.４）
Accelerated testing was performed for all 
new drug products（data not shown）.
Photostability Testing
According to ICHQ１B,２） studies on new 
drug products are conducted in a sequential 
manner, starting with the testing of com-
pletely exposed products and progressing, as 
necessary, to products in the immediate pack 
followed by those then in the marketing 
pack.　Testing continues until the results 
demonstrate that the drug product is ade-
quately protected from exposure to light.
Seventy-eight new drug products were 
founds to be optically stable and ４９ were 
optically unstable（Fig. ３）.　New drug prod-
ucts that appeared unstable in photostability 
testing were stored in the dark.
Consequently, we concluded that the 
storage conditions were appropriate.
In conclusion, our review, based on ICH 
guidelines, describes １３４ new drug products 
approved in Japan in ２０１４, all of which were 
adequately tested.
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Fig. ３　Classification of drugs based on photostability testing
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